542 Views | 456 Downloads
Correspondence: S. N. Taylor, LSU Health Sciences Center, Section of Infectious Diseases, 3308 Tulane Ave., 5th Floor, New Orleans, Louisiana 70119, Staylo2@lsuhsc.edu
Acknowledgments: We thank the participants, clinical staff, and investigators of this study for their participation, specifically Dr Susan Philip who enrolled the highest number of Microbiological Evaluable participants.
We also thank the PPD team for their study contributions and Jodi Stahlman and Monica McGee at PPD for manuscript editorial and writing assistance.
For laboratory contributions, we thank Q2 Solutions and the University of Alabama for their microbiology analyses and the GlaxoSmithKline genetics laboratory for their mutation analyses.
Disclosures: The study was sponsored by GlaxoSmithKline (Collegeville, Pennsylvania).
S. N. T. has received research support from Beckman Coulter, Becton Dickinson, Cepheid, GlaxoSmithKline (along with scientific advisory board and as a consultant), Hologic, Melinta, AstraZeneca, and Roche Molecular.
B. E. B. has received research support from Melinta, AstraZeneca, and Entasis.
C. A. T., N. E. S-O., C. R. P., A. R., M. H., and E. F. D. are employees at GlaxoSmithKline.
Medical writing assistance was provided by PPD and funded by GlaxoSmithKline.
Authors were not paid for their contributions.
All other authors reported no conflicts of interest.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
This work was supported by GlaxoSmithKline.
This work was also supported in whole or in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under an Other Transaction Authority Agreement (HHSO100201300011C).
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.